GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » EPS (Diluted)

CTOR (Citius Oncology) EPS (Diluted) : $ (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology EPS (Diluted)?

Citius Oncology's Earnings per Share (Diluted) for the six months ended in Sep. 2024 was $-0.31.

Citius Oncology's EPS (Basic) for the six months ended in Sep. 2024 was $-0.31.

Citius Oncology's EPS without NRI for the six months ended in Sep. 2024 was $-0.31.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Citius Oncology EPS (Diluted) Historical Data

The historical data trend for Citius Oncology's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology EPS (Diluted) Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
EPS (Diluted)
-0.08 -0.18 -0.31

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
EPS (Diluted) -0.08 -0.18 -0.31

Competitive Comparison of Citius Oncology's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citius Oncology's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's PE Ratio distribution charts can be found below:

* The bar in red indicates where Citius Oncology's PE Ratio falls into.


Citius Oncology EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Citius Oncology's Diluted EPS for the fiscal year that ended in Sep. 2024 is calculated as

Diluted EPS (A: Sep. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-21.149-0)/68.054
=-0.31

Citius Oncology's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-21.149-0)/68.054
=-0.31

Citius Oncology  (NAS:CTOR) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Citius Oncology EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Citius Oncology's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » EPS (Diluted)
Comparable Companies
INCR ASRT CPIX DERM RGC OPTN RMTI MRMD ETST SCYX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ XTAE:TEVA NSE:DIVISLAB HKSE:03692
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.